Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Total Non-Current Liabilities history spans 7 years, with the latest figure at $39.8 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 104.6% to $39.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.8 million through Dec 2025, up 104.6% year-over-year, with the annual reading at $39.8 million for FY2025, 104.6% up from the prior year.
  • Total Non-Current Liabilities came in at $39.8 million for Q4 2025, up from $20.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $273.7 million in Q2 2021 to a low of $14.6 million in Q1 2023.
  • The 5-year median for Total Non-Current Liabilities is $26.2 million (2024), against an average of $52.1 million.
  • Year-over-year, Total Non-Current Liabilities plummeted 89.81% in 2022 and then skyrocketed 193.33% in 2024.
  • Atea Pharmaceuticals' Total Non-Current Liabilities stood at $56.9 million in 2021, then crashed by 63.29% to $20.9 million in 2022, then surged by 62.91% to $34.0 million in 2023, then tumbled by 42.84% to $19.4 million in 2024, then soared by 104.6% to $39.8 million in 2025.
  • Per Business Quant, the three most recent readings for AVIR's Total Non-Current Liabilities are $39.8 million (Q4 2025), $20.4 million (Q3 2025), and $20.5 million (Q2 2025).